143 related articles for article (PubMed ID: 37007541)
1. Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic efficacy in esophageal cancer.
Li C; Zhu M; Lu Q; Yu B; Yang Y; Li B; Peng Z; Li Z
Ann Transl Med; 2023 Mar; 11(5):193. PubMed ID: 37007541
[TBL] [Abstract][Full Text] [Related]
2. OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma.
Li C; Yan Y; Ji W; Bao L; Qian H; Chen L; Wu M; Chen H; Li Z; Su C
PLoS One; 2012; 7(11):e49693. PubMed ID: 23185410
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo.
Shen W; Wang CY; Wang XH; Fu ZX
J Exp Clin Cancer Res; 2009 Jun; 28(1):81. PubMed ID: 19527508
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of association of OCT4 with LEF1 expression in esophageal squamous cell carcinoma and their impact on epithelial-mesenchymal transition, invasion, and migration.
Zhao Y; Li C; Huang L; Niu S; Lu Q; Gong D; Huang S; Yuan Y; Chen H
Cancer Med; 2018 Aug; 7(8):3977-3987. PubMed ID: 29974668
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.
Liu C; Sun B; An N; Tan W; Cao L; Luo X; Yu Y; Feng F; Li B; Wu M; Su C; Jiang X
Mol Oncol; 2011 Dec; 5(6):545-54. PubMed ID: 22032823
[TBL] [Abstract][Full Text] [Related]
7. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy.
Wang W; Ji W; Hu H; Ma J; Li X; Mei W; Xu Y; Hu H; Yan Y; Song Q; Li Z; Su C
Oncotarget; 2014 Jan; 5(1):150-60. PubMed ID: 24473833
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
9. [Construction of adenovirus carrying dual-target shRNA for Oct-4 and Survivin and its inhibitory effect on human hepatocellular carcinoma cells].
Wang D; Wang J; Li L; Chen J; Su C
Sheng Wu Gong Cheng Xue Bao; 2012 May; 28(5):623-31. PubMed ID: 22916500
[TBL] [Abstract][Full Text] [Related]
10. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.
Lu CS; Hsieh JL; Lin CY; Tsai HW; Su BH; Shieh GS; Su YC; Lee CH; Chang MY; Wu CL; Shiau AL
Gene Ther; 2015 Apr; 22(4):305-15. PubMed ID: 25588741
[TBL] [Abstract][Full Text] [Related]
12. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
13. Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.
Hu CY; Hung CF; Chen PC; Hsu JY; Wang CT; Lai MD; Tsai YS; Shiau AL; Shieh GS; Wu CL
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37892972
[TBL] [Abstract][Full Text] [Related]
14. Combined oncolytic adenovirus carrying MnSOD and mK5 genes both regulated by survivin promoter has a synergistic inhibitory effect on gastric cancer.
Liu SS; Hu JQ; Gu JF; Ni AM; Tang WH; Liu XY
Neoplasma; 2022 Jan; 69(1):36-48. PubMed ID: 34881625
[TBL] [Abstract][Full Text] [Related]
15. A dual-regulated oncolytic adenovirus carrying TAp63 gene exerts potent antitumor effect on colorectal cancer cells.
Luo Q; Liu H; Zhang Z; Basnet S; Dai Z; Li S; Wang Y; Xu B; Ge H
Am J Transl Res; 2017; 9(6):2966-2974. PubMed ID: 28670384
[TBL] [Abstract][Full Text] [Related]
16. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
17. [Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6].
Wang Q; Wang YH; Li Y; Xing M; Zhou DM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):71-76. PubMed ID: 35048603
[TBL] [Abstract][Full Text] [Related]
18. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
19. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
20. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
